|
|
|
|
|
My Recent Searches
|
|
|
|
|
|
|
Taysha Gene Therapies, Inc. (TSHA) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30
|
|
Download |
|
|
|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
186,960,000 |
Market
Cap: |
N/A |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$ - $ |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Taysha Gene Therapies is a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system in both rare and large patient populations. Co. owns the exclusive worldwide rights to a clinical-stage, intrathecally dosed AAV9 gene therapy program, known as TSHA-120, for the treatment of giant axonal neuropathy (GAN). GAN is a rare autosomal recessive disease of the central and peripheral nervous systems caused by loss-of-function gigaxonin gene mutations. TSHA-120 is an AAV9 self-complementary viral vector encoding the full length human gigaxonin protein.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
100,000 |
17,905,000 |
19,405,000 |
Total Buy Value |
$0 |
$163,000 |
$16,186,400 |
$19,186,400 |
Total People Bought |
0 |
1 |
5 |
5 |
Total Buy Transactions |
0 |
1 |
7 |
8 |
Total Shares Sold |
0 |
0 |
582,095 |
677,095 |
Total Sell Value |
$0 |
$0 |
$465,624 |
$813,892 |
Total People Sold |
0 |
0 |
2 |
3 |
Total Sell Transactions |
0 |
0 |
7 |
16 |
End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Manning Paul B |
Director |
|
2021-05-14 |
4 |
B |
$20.98 |
$251,760 |
D/D |
12,000 |
12,000 |
3.92 |
- |
|
Nolan Sean P. |
Director |
|
2020-09-28 |
4 |
A |
$0.00 |
$0 |
I/I |
1,091,101 |
1,091,101 |
|
- |
|
Manning Paul B |
Director |
|
2020-09-28 |
4 |
A |
$0.00 |
$0 |
I/I |
5,295,307 |
2,020,102 |
|
- |
|
Nagendran Sukumar |
Director |
|
2020-09-28 |
4 |
A |
$0.00 |
$0 |
D/D |
19,226 |
19,226 |
|
- |
|
Prasad Suyash |
CMO and Head of R&D |
|
2020-09-28 |
4 |
A |
$0.00 |
$0 |
D/D |
3,844 |
672,589 |
|
- |
|
Alam Kamran |
Chief Financial Officer |
|
2020-09-23 |
4 |
A |
$0.00 |
$0 |
D/D |
331,121 |
331,121 |
|
- |
|
Prasad Suyash |
CMO and Head of R&D |
|
2020-09-23 |
4 |
A |
$0.00 |
$0 |
D/D |
668,745 |
668,745 |
|
- |
|
Session R.a. Ii |
President and CEOOfficer |
|
2020-09-23 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
282,180 |
|
- |
|
Session R.a. Ii |
President and CEOOfficer |
|
2020-09-23 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
9,148,402 |
|
- |
|
59 Records found
|
|
Page 3 of 3 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|